Icon

INFUGEM (nda208313)- (EQ 1200MG BASE/120ML (EQ 10MG BASE/ML),EQ 1300MG BASE/130ML (EQ 10MG BASE/ML),EQ 1400MG BASE/140ML (EQ 10MG BASE/ML),EQ 1500MG BASE/150ML (EQ 10MG BASE/ML),EQ 1600MG BASE/160ML (EQ 10MG BASE/ML),EQ 1700MG BASE/170ML (EQ 10MG BASE/ML),EQ 1800MG BASE/180ML (EQ 10MG BASE/ML),EQ 1900MG BASE/190ML (EQ 10MG BASE/ML),EQ 2000MG BASE/200ML (EQ 10MG BASE/ML),EQ 2200MG BASE/220ML (EQ 10MG BASE/ML))

GEMCITABINE HYDROCHLORIDE SUN PHARM
EQ 1200MG BASE/120ML (EQ 10MG BASE/ML),EQ 1300MG BASE/130ML (EQ 10MG BASE/ML),EQ 1400MG BASE/140ML (EQ 10MG BASE/ML),EQ 1500MG BASE/150ML (EQ 10MG BASE/ML),EQ 1600MG BASE/160ML (EQ 10MG BASE/ML),EQ 1700MG BASE/170ML (EQ 10MG BASE/ML),EQ 1800MG BASE/180ML (EQ 10MG BASE/ML),EQ 1900MG BASE/190ML (EQ 10MG BASE/ML),EQ 2000MG BASE/200ML (EQ 10MG BASE/ML),EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)
No Yes
2033-Jul-01 Expired
None None
None No
INFUGEM is a nucleoside metabolic inhibitor indicated:  in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.  in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.  in combination with cisplatin, for the treatment of non-small cell lung cancer. (1.3)  as a single agent for the treatment of pancreatic cancer.
0 0 0
Total Other Developers 1
Drugs with Suitability No
EQ 1200MG BASE/120ML (EQ 10MG BASE/ML) ** ** - - -
EQ 1300MG BASE/130ML (EQ 10MG BASE/ML) ** ** - - -
EQ 1400MG BASE/140ML (EQ 10MG BASE/ML) ** ** - - -
EQ 1500MG BASE/150ML (EQ 10MG BASE/ML) ** ** - - -
EQ 1600MG BASE/160ML (EQ 10MG BASE/ML) ** ** - - -
EQ 1700MG BASE/170ML (EQ 10MG BASE/ML) ** ** - - -
EQ 1800MG BASE/180ML (EQ 10MG BASE/ML) ** ** - - -
EQ 1900MG BASE/190ML (EQ 10MG BASE/ML) ** ** - - -
EQ 2000MG BASE/200ML (EQ 10MG BASE/ML) ** ** - - -
EQ 2200MG BASE/220ML (EQ 10MG BASE/ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.